Mysildecard 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
IB/0013 
C.I.2.a - Change in the SPC, Labelling or PL of a 
30/11/2022 
SmPC 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
IB/0012 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
01/07/2022 
SmPC and PL 
To update section 4.5 of the SmPC to add a warning about 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
the increase in hypotension observed with concomitant use 
of sildenafil and sacubitril/valsartan. The Package leaflet is 
updated accordingly. 
IB/0011 
C.I.11.z - Introduction of, or change(s) to, the 
03/06/2022 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
T/0010 
Transfer of Marketing Authorisation 
07/10/2021 
28/10/2021 
SmPC, 
Labelling and 
PL 
R/0009 
Renewal of the marketing authorisation. 
20/05/2021 
16/07/2021 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II and PL 
the CHMP considered that the benefit-risk balance of 
Mysildecard in the approved indication remains favourable 
and therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
N/0008 
Minor change in labelling or package leaflet not 
14/01/2021 
16/07/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0007/G 
This was an application for a group of variations. 
17/11/2020 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
Page 2/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0006 
C.I.2.a - Change in the SPC, Labelling or PL of a 
04/11/2020 
16/07/2021 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0005 
B.II.b.2.c.1 - Change to importer, batch release 
30/04/2020 
25/06/2020 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0004 
C.I.2.a - Change in the SPC, Labelling or PL of a 
09/07/2019 
25/06/2020 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0003 
B.III.1.a.2 - Submission of a new/updated or 
25/03/2019 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
N/0002 
Minor change in labelling or package leaflet not 
22/03/2019 
25/06/2020 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
IAIN/0001/G 
This was an application for a group of variations. 
16/03/2017 
n/a 
B.II.b.2.c.1 - Change to importer, batch release 
Page 3/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
Page 4/4 
 
 
 
 
 
 
 
